Our results demonstrate that the deletion of the C-terminal tail of HMGB1 increases its activity towards a large panel of cancer cells including cells resistant to DNA-targeted chemotherapy without affecting the viability of normal immortalized fibroblasts. The gene discussed is HMGB1; the disease is cancer.